Symbols / LGVN
LGVN Chart
About
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.40M |
| Enterprise Value | 4.14M | Income | -21.34M | Sales | 1.44M |
| Book/sh | 0.47 | Cash/sh | 0.43 | Dividend Yield | — |
| Payout | 0.00% | Employees | 25 | IPO | — |
| P/E | — | Forward P/E | -0.38 | PEG | — |
| P/S | 8.63 | P/B | 1.23 | P/C | — |
| EV/EBITDA | -0.20 | EV/Sales | 2.88 | Quick Ratio | 1.88 |
| Current Ratio | 2.09 | Debt/Eq | 9.86 | LT Debt/Eq | — |
| EPS (ttm) | -0.98 | EPS next Y | -1.53 | EPS Growth | — |
| Revenue Growth | -82.30% | Earnings | 2026-02-26 | ROA | -60.95% |
| ROE | -119.92% | ROIC | — | Gross Margin | 74.88% |
| Oper. Margin | -53.36% | Profit Margin | 0.00% | Shs Outstand | 19.85M |
| Shs Float | 17.24M | Short Float | 6.80% | Short Ratio | 5.65 |
| Short Interest | — | 52W High | 1.92 | 52W Low | 0.49 |
| Beta | 0.20 | Avg Volume | 283.92K | Volume | 38.37K |
| Target Price | $5.82 | Recom | Strong_buy | Prev Close | $0.57 |
| Price | $0.58 | Change | 2.78% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.82
Mean price target
2. Current target
$0.55
Latest analyst target
3. DCF / Fair value
$-9.00
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.55
Low
$3.00
High
$10.45
Mean
$5.82
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-15 | main | Roth Capital | Buy → Buy | $3 |
| 2025-03-21 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-12-05 | init | Roth MKM | — → Buy | $10 |
| 2024-11-25 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-09-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-27 | main | Maxim Group | Buy → Buy | $6 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-07-31 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-07-29 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-04-29 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-12-04 | init | HC Wainwright & Co. | — → Buy | $6 |
| 2023-05-16 | reit | EF Hutton | Buy → Buy | $13 |
| 2023-05-09 | reit | EF Hutton | — → Buy | $13 |
| 2023-03-27 | reit | EF Hutton | — → Buy | $13 |
| 2023-01-10 | main | EF Hutton | — → Buy | $13 |
| 2022-03-24 | init | Maxim Group | — → Buy | $14 |
| 2022-01-05 | init | EF Hutton | — → Buy | $20 |
- Stem cell therapy for rare infant heart defect moves into key FDA talks - Stock Titan Mon, 26 Jan 2026 08
- Is Longeveron Stock Built to Withstand More Downside? - Trefis Sun, 21 Dec 2025 08
- Longeveron Appoints New CEO Amid Cost-Cutting Initiatives - The Globe and Mail Sat, 14 Feb 2026 08
- Longeveron Inc (LGVN) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance ue, 12 Aug 2025 07
- Can LGVN stock double in the next year - 2025 Fundamental Recap & AI Forecasted Entry and Exit Points - baoquankhu1.vn ue, 24 Feb 2026 15
- Longeveron launches offering of up to 11.8M shares via warrants and stock units - MSN ue, 24 Feb 2026 20
- Longeveron Faces Nasdaq Delisting Notice for Stock Price - TipRanks Fri, 26 Sep 2025 07
- Can Longeveron (NASDAQ:LGVN) Afford To Invest In Growth? - simplywall.st hu, 10 Jul 2025 07
- MODD, LAB, HOWL, COGT, LGVN, ABCL Lead Biotech After-Hours Rally - Nov 26 - Nasdaq hu, 27 Nov 2025 08
- Longeveron closes $5 million public offering of common stock By Investing.com - Investing.com Nigeria Sat, 08 Nov 2025 08
- Congress renews voucher that may speed Longeveron heart therapy for babies - Stock Titan hu, 05 Feb 2026 08
- Longeveron Appoints New CEO to Drive Growth - Intellectia AI Fri, 13 Feb 2026 08
- Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2025 Result - Yahoo Finance Mon, 03 Nov 2025 08
- Earnings call transcript: Longeveron sees stock surge after Q2 2025 earnings - Investing.com Wed, 13 Aug 2025 07
- Longeveron Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st Fri, 15 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 34000 | — | — | Stock Award(Grant) at price 0.00 per share. | PALETTA GEORGE A JR. | Director | — | 2025-10-01 00:00:00 | D |
| 1 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | POWELL JAMES NATHANIEL | Chief Executive Officer | — | 2025-09-04 00:00:00 | D |
| 2 | 11766 | 8181.0 | — | Purchase at price 0.70 per share. | BALUCH KHOSO | Director | — | 2025-08-11 00:00:00 | D |
| 3 | 11766 | 8181.0 | — | Purchase at price 0.70 per share. | LOCKLEAR LISA | Chief Financial Officer | — | 2025-08-11 00:00:00 | D |
| 4 | 17000 | — | — | Stock Award(Grant) at price 0.00 per share. | BALUCH KHOSO | Director | — | 2025-07-15 00:00:00 | D |
| 5 | 17000 | — | — | Stock Award(Grant) at price 0.00 per share. | SOFFER ROCK J | Director | — | 2025-07-15 00:00:00 | D |
| 6 | 102000 | — | — | Stock Award(Grant) at price 0.00 per share. | LEHR PAUL T | General Counsel | — | 2025-07-15 00:00:00 | D |
| 7 | 17000 | — | — | Stock Award(Grant) at price 0.00 per share. | UNGARO URSULA | Director | — | 2025-07-15 00:00:00 | D |
| 8 | 180000 | — | — | Stock Award(Grant) at price 0.00 per share. | HASHAD MOHAMED WA'EL AHMED | Chief Executive Officer | — | 2025-07-15 00:00:00 | D |
| 9 | 102000 | — | — | Stock Award(Grant) at price 0.00 per share. | AGAFONOVA NATALIYA | Officer | — | 2025-07-15 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.56M | -20.05M | -15.75M | -16.43M |
| TotalUnusualItems | 0.00 | -30.00K | -1.40M | 300.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -30.00K | -1.40M | 300.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.97M | -21.41M | -18.84M | -17.05M |
| ReconciledDepreciation | 958.00K | 946.00K | 893.00K | 914.00K |
| ReconciledCostOfRevenue | 508.00K | 488.00K | 725.00K | 716.00K |
| EBITDA | -15.56M | -20.08M | -17.15M | -16.13M |
| EBIT | -16.52M | -21.03M | -18.04M | -17.04M |
| NetInterestIncome | 0.00 | -4.00K | ||
| InterestExpense | 0.00 | 4.00K | ||
| NormalizedIncome | -15.97M | -21.38M | -17.44M | -17.34M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.97M | -21.41M | -18.84M | -17.05M |
| TotalExpenses | 18.91M | 21.74M | 19.27M | 18.76M |
| TotalOperatingIncomeAsReported | -16.52M | -21.03M | -18.04M | -17.46M |
| DilutedAverageShares | 9.41M | 2.17M | 2.10M | 1.89M |
| BasicAverageShares | 9.41M | 2.17M | 2.10M | 1.89M |
| DilutedEPS | -2.62 | -10.22 | -9.00 | -9.00 |
| BasicEPS | -2.62 | -10.22 | -9.00 | -9.00 |
| DilutedNIAvailtoComStockholders | -24.62M | -22.21M | -18.84M | -17.05M |
| NetIncomeCommonStockholders | -24.62M | -22.21M | -18.84M | -17.05M |
| OtherunderPreferredStockDividend | 8.65M | 798.00K | 0.00 | |
| NetIncome | -15.97M | -21.41M | -18.84M | -17.05M |
| NetIncomeIncludingNoncontrollingInterests | -15.97M | -21.41M | -18.84M | -17.05M |
| NetIncomeContinuousOperations | -15.97M | -21.41M | -18.84M | -17.05M |
| PretaxIncome | -15.97M | -21.41M | -18.84M | -17.05M |
| OtherIncomeExpense | 549.00K | -384.00K | -792.00K | 415.00K |
| OtherNonOperatingIncomeExpenses | 549.00K | -354.00K | 606.00K | 115.00K |
| SpecialIncomeCharges | 0.00 | -30.00K | -1.40M | 300.00K |
| OtherSpecialCharges | 30.00K | 1.40M | -300.00K | |
| NetNonOperatingInterestIncomeExpense | 0.00 | -4.00K | ||
| InterestExpenseNonOperating | 0.00 | 4.00K | ||
| OperatingIncome | -16.52M | -21.03M | -18.04M | -17.46M |
| OperatingExpense | 18.41M | 21.25M | 18.54M | 18.05M |
| ResearchAndDevelopment | 8.14M | 9.07M | 9.37M | 7.09M |
| SellingGeneralAndAdministration | 10.27M | 12.18M | 9.17M | 10.95M |
| SellingAndMarketingExpense | 783.00K | 1.05M | 1.21M | |
| GeneralAndAdministrativeExpense | 10.27M | 12.18M | 8.12M | 9.74M |
| OtherGandA | 10.27M | 12.18M | 8.12M | 9.74M |
| GrossProfit | 1.88M | 221.00K | 497.00K | 590.00K |
| CostOfRevenue | 508.00K | 488.00K | 725.00K | 716.00K |
| TotalRevenue | 2.39M | 709.00K | 1.22M | 1.31M |
| OperatingRevenue | 2.39M | 709.00K | 1.22M | 1.31M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 14.89M | 2.51M | 2.10M | 2.09M |
| ShareIssued | 14.89M | 2.51M | 2.10M | 2.09M |
| TotalDebt | 1.45M | 2.04M | 2.60M | 3.14M |
| TangibleBookValue | 19.49M | 4.45M | 18.09M | 35.12M |
| InvestedCapital | 21.89M | 6.74M | 20.50M | 37.45M |
| WorkingCapital | 17.04M | 1.96M | 15.41M | 32.67M |
| NetTangibleAssets | 19.49M | 4.45M | 18.09M | 35.12M |
| CapitalLeaseObligations | 1.45M | 2.04M | 2.60M | 3.14M |
| CommonStockEquity | 21.89M | 6.74M | 20.50M | 37.45M |
| TotalCapitalization | 21.89M | 6.74M | 20.50M | 37.45M |
| TotalEquityGrossMinorityInterest | 21.89M | 6.74M | 20.50M | 37.45M |
| StockholdersEquity | 21.89M | 6.74M | 20.50M | 37.45M |
| OtherEquityInterest | -100.00K | -100.00K | -100.00K | |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -357.00K | 0.00 | |
| OtherEquityAdjustments | -357.00K | |||
| RetainedEarnings | -109.61M | -84.98M | -62.77M | -43.94M |
| AdditionalPaidInCapital | 131.48M | 91.82M | 83.71M | 81.47M |
| CapitalStock | 14.00K | 2.00K | 21.00K | 21.00K |
| CommonStock | 14.00K | 2.00K | 21.00K | 21.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.67M | 5.34M | 6.91M | 5.31M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.09M | 1.45M | 2.04M | 2.60M |
| OtherNonCurrentLiabilities | 265.00K | |||
| LongTermDebtAndCapitalLeaseObligation | 824.00K | 1.45M | 2.04M | 2.60M |
| LongTermCapitalLeaseObligation | 824.00K | 1.45M | 2.04M | 2.60M |
| CurrentLiabilities | 2.58M | 3.89M | 4.87M | 2.71M |
| OtherCurrentLiabilities | 1.40M | |||
| CurrentDeferredLiabilities | 40.00K | 506.00K | 506.00K | 199.00K |
| CurrentDeferredRevenue | 40.00K | 506.00K | 506.00K | 199.00K |
| CurrentDebtAndCapitalLeaseObligation | 623.00K | 593.00K | 564.00K | 537.00K |
| CurrentCapitalLeaseObligation | 623.00K | 593.00K | 564.00K | 537.00K |
| CurrentNotesPayable | 0.00 | |||
| PayablesAndAccruedExpenses | 1.92M | 2.79M | 2.40M | 1.97M |
| CurrentAccruedExpenses | 1.82M | 2.15M | 650.00K | 1.33M |
| Payables | 99.00K | 638.00K | 1.75M | 645.00K |
| AccountsPayable | 99.00K | 638.00K | 1.75M | 645.00K |
| TotalAssets | 25.56M | 12.08M | 27.41M | 42.77M |
| TotalNonCurrentAssets | 5.93M | 6.23M | 7.13M | 7.39M |
| OtherNonCurrentAssets | 202.00K | 193.00K | 244.00K | 177.00K |
| GoodwillAndOtherIntangibleAssets | 2.40M | 2.29M | 2.41M | 2.33M |
| OtherIntangibleAssets | 2.40M | 2.29M | 2.41M | 2.33M |
| NetPPE | 3.33M | 3.75M | 4.48M | 4.88M |
| AccumulatedDepreciation | -5.17M | -4.44M | -3.73M | -3.05M |
| GrossPPE | 8.51M | 8.19M | 4.48M | 7.92M |
| Leases | 4.40M | 4.33M | 4.33M | 4.32M |
| OtherProperties | 882.00K | 1.22M | 2.95M | 1.81M |
| MachineryFurnitureEquipment | 3.22M | 2.64M | 2.35M | 1.79M |
| BuildingsAndImprovements | 882.00K | 1.22M | 1.53M | 1.81M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 19.62M | 5.85M | 20.28M | 35.38M |
| OtherCurrentAssets | 308.00K | 376.00K | 404.00K | 282.00K |
| CurrentDeferredAssets | 0.00 | |||
| PrepaidAssets | 282.00K | |||
| Receivables | 84.00K | 111.00K | 218.00K | 55.00K |
| OtherReceivables | 59.00K | 96.00K | 218.00K | 55.00K |
| AccountsReceivable | 25.00K | 15.00K | 0.00 | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 19.23M | 5.36M | 19.66M | 35.04M |
| OtherShortTermInvestments | 0.00 | 412.00K | 9.15M | 9.38M |
| CashAndCashEquivalents | 19.23M | 4.95M | 10.50M | 25.66M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -14.86M | -19.70M | -14.82M | -10.95M |
| RepaymentOfDebt | 0.00 | -188.00K | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 12.87M | 5.34M | 0.00 | 45.19M |
| CapitalExpenditure | -992.00K | -694.00K | -856.00K | -1.31M |
| EndCashPosition | 19.23M | 4.95M | 10.50M | 25.66M |
| BeginningCashPosition | 4.95M | 10.50M | 25.66M | 816.00K |
| ChangesInCash | 14.28M | -5.55M | -15.15M | 24.84M |
| FinancingCashFlow | 28.79M | 5.26M | -509.00K | 45.17M |
| CashFlowFromContinuingFinancingActivities | 28.79M | 5.26M | -509.00K | 45.17M |
| NetOtherFinancingCharges | -266.00K | -174.00K | -511.00K | -451.00K |
| ProceedsFromStockOptionExercised | 16.19M | 98.00K | 2.00K | 623.00K |
| NetCommonStockIssuance | 12.87M | 5.34M | 0.00 | 45.19M |
| CommonStockIssuance | 12.87M | 5.34M | 0.00 | 45.19M |
| NetIssuancePaymentsOfDebt | 0.00 | -188.00K | ||
| NetShortTermDebtIssuance | 0.00 | -38.00K | ||
| ShortTermDebtPayments | 0.00 | -38.00K | ||
| ShortTermDebtIssuance | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | -150.00K | ||
| LongTermDebtPayments | 0.00 | -150.00K | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -640.00K | 8.19M | -677.00K | -10.70M |
| CashFlowFromContinuingInvestingActivities | -640.00K | 8.19M | -677.00K | -10.70M |
| NetInvestmentPurchaseAndSale | 352.00K | 8.88M | 179.00K | -9.47M |
| SaleOfInvestment | 352.00K | 8.88M | ||
| NetIntangiblesPurchaseAndSale | -337.00K | -393.00K | -287.00K | -980.00K |
| PurchaseOfIntangibles | -337.00K | -393.00K | -287.00K | -980.00K |
| NetPPEPurchaseAndSale | -655.00K | -301.00K | -569.00K | -245.00K |
| SaleOfPPE | 0.00 | 85.00K | ||
| PurchaseOfPPE | -655.00K | -301.00K | -569.00K | -330.00K |
| OperatingCashFlow | -13.87M | -19.00M | -13.97M | -9.64M |
| CashFlowFromContinuingOperatingActivities | -13.87M | -19.00M | -13.97M | -9.64M |
| InterestReceivedCFO | 60.00K | 220.00K | ||
| ChangeInWorkingCapital | -1.24M | 321.00K | 238.00K | -1.09M |
| ChangeInOtherWorkingCapital | -720.00K | -254.00K | 110.00K | -66.00K |
| ChangeInOtherCurrentLiabilities | 265.00K | 0.00 | ||
| ChangeInOtherCurrentAssets | -9.00K | 51.00K | -15.00K | -4.00K |
| ChangeInPayablesAndAccruedExpense | -872.00K | 389.00K | 429.00K | -1.16M |
| ChangeInAccruedExpense | -332.00K | 1.50M | -677.00K | -214.00K |
| ChangeInPayable | -540.00K | -1.11M | 1.11M | -945.00K |
| ChangeInAccountPayable | -540.00K | -1.11M | 1.11M | -945.00K |
| ChangeInPrepaidAssets | 68.00K | 28.00K | -122.00K | -227.00K |
| ChangeInReceivables | 27.00K | 107.00K | -164.00K | 366.00K |
| OtherNonCashItems | -1.40M | |||
| StockBasedCompensation | 2.33M | 2.03M | 2.17M | 7.74M |
| UnrealizedGainLossOnInvestmentSecurities | 220.00K | 170.00K | 85.00K | |
| AssetImpairmentCharge | 0.00 | 290.00K | 0.00 | |
| DepreciationAmortizationDepletion | 958.00K | 946.00K | 893.00K | 914.00K |
| DepreciationAndAmortization | 958.00K | 946.00K | 893.00K | 914.00K |
| OperatingGainsLosses | 1.40M | -240.00K | ||
| GainLossOnInvestmentSecurities | 1.40M | |||
| GainLossOnSaleOfPPE | 0.00 | 60.00K | ||
| NetIncomeFromContinuingOperations | -15.97M | -21.41M | -18.84M | -17.05M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LGVN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|